SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses
- 15 December 2011
- Vol. 30 (9) , 1737-1745
- https://doi.org/10.1016/j.vaccine.2011.12.026
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- High‐throughput quantitative analysis of HIV‐1 and SIV‐specific ADCC‐mediating antibody responsesCytometry Part A, 2011
- A dynamic T cell–limited checkpoint regulates affinity-dependent B cell entry into the germinal centerThe Journal of Experimental Medicine, 2011
- Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidityVaccine, 2010
- Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infectionThe Journal of Experimental Medicine, 2009
- Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1The Journal of Experimental Medicine, 2009
- Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeysNature, 2008
- Macaques vaccinated with live-attenuated SIV control replication of heterologous virusThe Journal of Experimental Medicine, 2008
- Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVAVirology, 2007
- GM-CSF DNA: An adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccineVirology, 2007
- Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccinationJournal of Immunological Methods, 2007